文献速递结核与非结核分枝杆菌艾滋病与性传播感染

FujiLAM II assay 在晚期 HIV 门诊患者中检测结核的诊断准确性

Diagnostic Accuracy of the Updated FujiLAM II Assay to Detect Tuberculosis in Outpatients With Advanced HIV Disease.
PubMed 文献 · Clin Infect Dis · 2025-01-01

在乌干达 16 家诊所的晚期 HIV 门诊患者中开展前瞻性诊断准确性研究,评估 FujiLAM II 对确诊结核的检测性能。在 583 名受试者中,敏感度为 54%(25/46),特异度为 95%(326/342);CD4<100 cells/µL 者敏感度 69%、特异度 94%。结论认为 FujiLAM II 是一种中等敏感度、高特异度的非痰液即时结核诊断方法。

要点

  • FujiLAM II 检测确诊结核的敏感度为 54%(25/46),特异度为 95%(326/342)。
  • CD4<100 cells/µL 者敏感度 69%(95%CI 53%-85%),特异度 94%(95%CI 90%-97%)。
  • CRP≥5 mg/L 者敏感度 62%(95%CI 46%-77%),特异度 93%(95%CI 89%-98%)。

核心结论

  • FujiLAM II 是一种即时、非痰液的结核诊断方法,在晚期 HIV 门诊患者中具有中等敏感度和高特异度。

研究设计与样本

  • 在乌干达 16 家诊所开展的前瞻性诊断准确性研究,对晚期 HIV 门诊成人的冻存尿液标本运行 FujiLAM II 检测。
  • 以 Xpert 或分枝杆菌培养阳性为确诊结核,比较 FujiLAM II 对确诊结核与无结核者的诊断性能。
  • 在预设亚组中评估敏感度和特异度:CD4<100 cells/µL 对比 100-200 cells/µL、抗逆转录病毒治疗初治对比经治、CRP<5 mg/L 对比≥5 mg/L。

主要发现

  • 在 583 名接受 FujiLAM II 检测的参与者中,检测确诊结核的敏感度为 54%(25/46)(95%CI 40%-69%),排除结核的特异度为 95%(326/342)(95%CI 93%-98%)。
  • CD4 细胞计数<100 cells/µL 的参与者中,FujiLAM II 敏感度为 69%(95%CI 53%-85%),特异度为 94%(95%CI 90%-97%)。
  • 血清 CRP≥5 mg/L 的参与者中,FujiLAM II 敏感度为 62%(95%CI 46%-77%),特异度为 93%(95%CI 89%-98%)。

关键数值与推荐

  • 确诊结核定义:Xpert 或分枝杆菌培养阳性。
  • 总体敏感度 54%(25/46)(95%CI 40%-69%),特异度 95%(326/342)(95%CI 93%-98%)。
  • CD4<100 cells/µL 亚组敏感度 69%(95%CI 53%-85%),特异度 94%(95%CI 90%-97%)。
  • CRP≥5 mg/L 亚组敏感度 62%(95%CI 46%-77%),特异度 93%(95%CI 89%-98%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An urgent need exists for point-of-care diagnostics to detect tuberculosis (TB) among people with advanced human immunodeficiency virus (HIV) disease. The Fujifilm SILVAMP TB LAM (FujiLAM II) is a novel point-of-care assay that detects mycobacterial lipoarabinomannan (LAM) antigen in the urine to identify TB. We present a validation of the FujiLAM II assay on prospectively collected urine samples from outpatient adults with advanced HIV disease in Uganda. METHODS: We performed a prospective diagnostic accuracy study of the FujiLAM II assay among outpatients with advanced HIV disease at 16 clinics Uganda. FujiLAM II was run on cryopreserved urine. We determined diagnostic performance for the FujiLAM II test against the cases of confirmed TB (Xpert or mycobacterial culture positive) versus cases without TB. We additionally assessed sensitivity and specificity of the FujiLAM II assay as compared with confirmed TB among pre-specified subgroups: CD4 <100 cells/µL versus 100-200 cells/µL, antiretroviral therapy (ART) naive versus experienced, and CRP <5 mg/L versus ≥5 mg/L. RESULTS: Among 583 participants who had FujiLAM II testing performed, the FujiLAM II assay demonstrated 54% (25/46) (95% confidence interval [CI]: 40%-69%) sensitivity to identify confirmed TB and 95% (326/342) (95% CI: 93% to 98%) specificity to identify the absence of TB. Among participants with CD4 cell counts <100 cells/µL, FujiLAM II sensitivity was 69% (95% CI: 53%-85%) and specificity was 94% (95% CI: 90%-97%). Among participants with serum C-reactive protein (CRP) ≥5 mg/L, the FujiLAM II assay exhibited a sensitivity of 62% (95% CI: 46%-77%) and specificity of 93% (95% CI: 89%-98%). CONCLUSIONS: FujiLAM II is a point-of-care, non-sputum based TB diagnostic with moderate sensitivity and high specificity in outpatients with advanced HIV disease.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Adzemovic T, Nalintya E, Fieberg A, et al. Diagnostic Accuracy of the Updated FujiLAM II Assay to Detect Tuberculosis in Outpatients With Advanced HIV Disease. Clin Infect Dis. 2025. PMID: 40130995. doi:10.1093/cid/ciaf079

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。